Goldman Sachs Group Inc. is considering sweetening the terms on $1.73 billion of leveraged loans tied to chemical maker Arclin Inc.'s acquisition of DuPont de Nemours Inc.'s Aramids business. The move comes as Goldman Sachs evaluates adjustments to make the financing more attractive to investors in a challenging market environment. The leveraged loan market has faced headwinds recently, with investors demanding higher yields on riskier corporate debt.

The potential sweetening of terms highlights the complexities of financing large-scale acquisitions in the chemical sector. Arclin Inc.'s purchase of DuPont's Aramid business represents a significant strategic move in the specialty materials market. Aramid fibers, known for their strength and heat resistance, are used in various applications from body armor to aerospace components. The deal's financing structure reflects broader trends in leveraged buyout activity and the challenges faced by investment banks in syndicating large loans.

This development underscores the delicate balance between deal sponsors and lenders in structuring acquisition financing. As market conditions evolve, Goldman Sachs must weigh the benefits of improved loan terms against potential impacts on the bank's own financial metrics. The outcome of these negotiations could set precedents for similar transactions in the industrial sector.